Luminex Corporation Announces Pricing of Public Offering of Common Stock

  
    
  
  
    
      Luminex Corporation (NASDAQ:LMNX) announced today the pricing of its 
      underwritten public offering of 3,500,000 shares of its common stock. 
      The Company has granted the underwriters a 30-day option to purchase up 
      to an additional 525,000 shares of common stock to cover 
      over-allotments, if any. The offering is expected to close on June 30, 
      2008.
    
    
      The offering price to public is $19.91 per share. Luminex estimates that 
      the net proceeds from the offering will be approximately $64.5 million, 
      after deducting estimated expenses and underwriting discounts and 
      commissions. Luminex intends to use the net proceeds from the offering 
      for general corporate purposes, including research and development, 
      potential acquisitions and capital expenditures.
    
    
      J.P. Morgan Securities Inc. and UBS Investment Bank are acting as joint 
      book-running managers for the offering. Avondale Partners, LLC, 
      Canaccord Adams Inc. and Leerink Swann LLC are acting as co-managers for 
      the offering.
    
    
      An automatically effective shelf registration statement has been filed 
      with the Securities and Exchange Commission which covers these 
      securities. The offering is being made solely by means of a prospectus 
      and prospectus supplement. Copies of the prospectus and related 
      prospectus supplement may be obtained by mail from: JPMorgan, National 
      Statement Processing, Prospectus Library, 4 Chase Metrotech Center, CS 
      Level, Brooklyn, NY 11245, telephone: [phone] or UBS Securities 
      LLC, 299 Park Avenue, New York, NY 10171 Attn: Prospectus Department, or 
      by telephone toll free at 888-827-7275, extension 3884. An electronic 
      copy of the prospectus and related preliminary prospectus supplement are 
      available on the website of the Securities and Exchange Commission at http://www.sec.gov.
    
    
      This press release does not constitute an offer to sell or the 
      solicitation of an offer to buy the shares of common stock or any other 
      securities, nor will there be any sale of the shares of common stock or 
      any other securities in any state or jurisdiction in which such offer, 
      solicitation or sale would be unlawful prior to the registration or 
      qualification under the securities laws of any state or jurisdiction.
    
    
      About Luminex Corporation
    
    
      Luminex develops, manufactures and markets proprietary biological 
      testing technologies with applications throughout the life sciences 
      industry. The Company’s xMAP® 
      system is an open-architecture, multi-analyte technology platform that 
      delivers fast, accurate and cost-effective bioassay results to markets 
      as diverse as pharmaceutical drug discovery, clinical diagnostics and 
      biomedical research, including the genomics and proteomics research 
      markets. The Company’s xMAP® 
      technology is sold worldwide and is in use in leading research 
      laboratories as well as major pharmaceutical, diagnostic and 
      biotechnology companies. Further information on Luminex or xMAP® 
      can be obtained on the Internet at http://www.luminexcorp.com.
    
    
      Statements contained in this press release that are not historical 
      facts are "forward-looking" statements within the meaning of the federal 
      securities laws. Forward-looking statements, including statements 
      regarding the completion of the public offering and any of the terms 
      thereof, are uncertain and subject to a variety of risks that could 
      cause actual results to differ materially from those expected by the 
      Company. Additional information regarding these and other risks 
      effecting the Company are contained in the Company's registration 
      statement and the prospectus supplement relating to the offering.